Femtech World

🚀 Five updates in femtech and women's health this week 🚀 💰 Uresta, a non-invasive solution for bladder leaks, is to launch in the United States following a $3m raise. Read more: https://lnkd.in/dWgijfYV 💉 Biotech company Anixa Biosciences, Inc. Biosciences has received a Notice of Allowance for a key patent application covering its ovarian cancer vaccine technology from the USPTO. Read more: https://lnkd.in/ezMKZSKj 🏥 GE HealthCare has launched the Invenia Automated Breast Ultrasound (ABUS) Premium, a 3D ultrasound offering advanced AI features to drive faster, reproducible screening and streamline exam readings on patients with dense breasts. Read more: https://lnkd.in/damG4CmC 🔍 US researchers have identified a key protein whose increased presence helps promote breast cancer brain metastasis, opening a new area of research into the condition. Read more: https://lnkd.in/eQfzG5jB 👨👩👦 A new study has uncovered a way to select viable sperm and prolong their viability in the lab, reducing one source of variability during the process – potentially helping to improve the success of IVF. Read more: https://lnkd.in/eM-3Rwmx Catch up on all this and more at femtechworld.co.uk #womenshealth #womenshealthmatters #femtech #healthtech #genderhealthgap #research #innovation #healthinequalities #women #medtech #healthequity #investment #funding #tech #femaleleadership #ai 

💵 Women’s earnings fall 10% four years after menopause diagnosis, study finds Women experience a significant fall in earnings in the years following a menopause diagnosis, with more women stopping work and others working fewer hours, according to a new study. Economists calculated that women experience a 4.3 per cent reduction in their earnings, on average, in the four years following a menopause diagnosis, with losses deepening to 10 per cent by the fourth year. This 10 per cent reduction in earnings is approximately half of the estimated 23 per cent loss of earnings experienced by new mothers, also known as the ‘child penalty’. The researchers analysed data from Sweden and Norway, including medical records that identified the date of the first menopause diagnosis. 💬 Lead author Professor Gabriella Conti (UCL Economics) said: “All women go through the menopause, but each woman’s experience is unique. We looked at women with a medical menopause diagnosis so these women may have experienced more severe symptoms than the general population. Our study shows how the negative impacts of the menopause penalty vary greatly between women.” Read more: https://lnkd.in/en96WAXh

💰 Uresta to launch in the US with $3m raise Uresta, a female-owned and led health startup, aims to help women to regain confidence and control over stress urinary incontinence (SUI) without surgery or absorbent products. To support its expansion, Uresta recently secured $3 million in funding, including $1.5 million from BDC Capital. This investment will accelerate the company’s U.S. launch and increase awareness of its approach to bladder leakage. 💬 Caroline Packard, PT, DPT, said: “Many women assume bladder leaks are just a normal part of ageing or childbirth, but that’s simply not true. Uresta is a game-changer, providing an easy-to-use, clinically proven option that allows women to get back to the activities they love without fear of leaks.” Read more: https://lnkd.in/dWgijfYV

📢 Interview: New report reveals why menopause care is a "workplace necessity" — for employee health and company performance A whitepaper published this month by sanoLiving, a digital health platform for women’s midlife care based in Canada, analyses real-world data from thousands of women using its flagship programme sanoMidLife. The results show that having access to comprehensive menopause care helps women manage symptoms, improving their well-being and engagement at work. - 80% of women using the platform experienced an overall improvement in quality of life. - 54% said their mood and emotional well-being improved. - 70% experienced an improvement in professional and personal relationships. - 50% reported an improvement in their ability to perform at work. CEO of sanoLiving, Angela Johnson, says: “Rising benefit costs—driven in part by midlife women’s unmet health needs—make menopause support a workplace necessity. When employers provide access to expert care—not just policies and accommodations— women can manage symptoms and stay productive." Read the full interview: https://lnkd.in/dCPzc_FP

💼 Endometriosis: What employers need to know With around 1 in 10 women affected by endometriosis, providing fertility support can improve wellbeing, productivity, and retention. In an increasingly diverse workplace, understanding and supporting the health challenges faced by employees is crucial. One condition that remains under the radar for many businesses is endometriosis, a condition that affects one in ten women. Dr Natasha Fernando, a practicing GP and Medical Director at Medichecks, offers her insights on the importance of supporting employees with endometriosis and how businesses can create a culture of understanding and care. Read more: https://lnkd.in/eHQtaVjq

💉 Ovarian cancer vaccine receives Notice of Allowance from USPTO Biotech company Anixa Biosciences has received a Notice of Allowance for a key patent application covering its ovarian cancer vaccine technology from the United States Patent and Trademark Office (USPTO). Anixa’s ovarian cancer vaccine uses a novel approach to preventing and treating ovarian cancer, particularly among high-risk populations such as those carrying BRCA mutations or with a family history of the disease. The patent includes broad claims related to methods of eliciting an immune response targeting Anti-Mullerian Hormone Receptor, Type II (AMHR2), a promising target for ovarian cancer prevention and treatment. 💬 Dr. Amit Kumar, chairman and CEO of Anixa Biosciences, Inc., said: “Receiving this Notice of Allowance from the USPTO is a significant milestone in our mission to develop a preventative and therapeutic ovarian cancer vaccine." Read more: https://lnkd.in/ezMKZSKj

🤰 Blood pressure patterns during pregnancy predict later hypertension risk Women with blood pressure levels in a range considered clinically normal during pregnancy, but no mid-pregnancy drop in blood pressure face an increased risk of developing hypertension in the five years after giving birth, a new study shows. These women, about 12% of the population studied, would not be flagged as high-risk by current medical guidelines, but the new findings could help identify them as candidates for early intervention. 💬 Shohreh Farzan, associate professor of population and public health sciences at the Keck School of Medicine of the University of Southern California USC said: "Because these women lacked traditional risk factors, they would not be alerted to their higher risk, nor would they be closely monitored for the development of high blood pressure." Read more: https://lnkd.in/d4PbDmrG

AI-driven platform to drive early cancer detection in dense breasts GE HealthCare has launched the Invenia Automated Breast Ultrasound (ABUS) Premium, a 3D ultrasound offering advanced AI features to drive faster, reproducible screening and streamline exam readings on patients with dense breasts. Early detection of breast cancer is critical, yet about one-third of cancers in dense breasts may go undetected by a mammogram, as the cancer can be masked within the dense tissue. ABUS has been designed to detect cancer in dense breasts, providing clearer and more detailed images. So far, it has been shown to improve the sensitivity of detecting invasive cancer in dense breasts when added to mammography. 💬 Karley Yoder, CEO of Comprehensive Care Ultrasound, GE HealthCare, said: “Women with dense breasts often face poorer outcomes due to malignancies detected at later, more advanced stages. Invenia ABUS Premium equipped with AI has the potential to optimise clinicians’ screening capabilities, enabling them to detect even small, early-stage cancers with a high degree of confidence in women with dense breasts." Read more: https://lnkd.in/damG4CmC

🚀 Five advances in femtech and women's health this week 🚀 🔍 A new discovery could pave the way for better approaches to prevent and detect high-grade serous ovarian cancer (HGSOC). Read more: https://lnkd.in/eTdzpXeD 🌺 Women’s precision healthcare company Evvy is launching Fertility Insights within its flagship Vaginal Microbiome Test, which provides insights on the role of the vaginal microbiome in fertility. Read more: https://lnkd.in/erTtr5Wf 🤩 Actress Halle Berry is teaming up with UCI researcher Pauline Maki to help advance menopause research and care. Read more: https://lnkd.in/eFTkU3NZ 🤝 Ema - The AI for Women, an AI-driven health technology leader, and MyUTI, a digital health pioneer in urinary and sexual health, are joining forces to combat a pervasive yet often minimised women’s health issue: urinary tract infections (UTIs). Read more: https://lnkd.in/ei7CQnsx 💰 Sigma Technology Group is partnering with Daya Ventures, a femtech venture studio, to close the US$1trn gender health gap.  Read more: https://lnkd.in/eMh24nhT Catch up at femtechworld.co.uk #womenshealth #womenshealthmatters #femtech #healthtech #genderhealthgap #research #innovation #healthinequalities #women #medtech #healthequity #investment #funding #tech #femaleleadership #ai 

💉 Research reveals why women experience worse side effects from weight loss drugs A new report uncovered significant biological differences between men and women in their response to popular weight loss medications like Ozempic and Zepbound. The report provides insights into why female patients, who make up 70 per cent of those taking GLP-1 drugs, experience more severe side effects despite achieving greater weight loss results. With obesity affecting two billion people worldwide and the treatment market projected to reach $200 billion by 2031, these findings could change how medications are prescribed to millions of patients. The study showed that women experience 2.5 times higher rates of nausea and vomiting compared to men when taking GLP-1 medications. Read more: https://lnkd.in/emXcZSvw